About Careers MedBlog Contact us

Discovery of a New Biomarker may Lead to New HIV Treatment

by Dr. Enozia Vakil on July 19, 2014 at 7:07 PM
Font : A-A+

 Discovery of a New Biomarker may Lead to New HIV Treatment

A potential biomarker that could be associated with participants who had a more profound viral load reduction following the vaccination was observed after an analysis of a therapeutic HIV vaccine. The results of this exploratory, ad hoc, subset analysis by St George's, University of London and Bionor Pharma were announced today at the AIDS 2014 Conference in Melbourne, Australia.

If confirmed, the biomarker may be able to predict which patients will benefit most from the therapeutic HIV vaccine candidate Vacc-4x, which is being developed by the Norwegian vaccine company Bionor Pharma.


St George's, University of London has had a long-standing collaboration with Bionor Pharma in a project to study HIV-associated immune activation that drives disease progression. Based on St George's work within this field, Bionor Pharma has developed a peptide (C5/gp41732-744 ) that can be used to detect antibodies against a part of the HIV envelope glycoprotein. The presence of antibodies to this part of HIV has been associated with slowed disease progression in the absence of combination antiretroviral therapy (ART).

Analysis of antibody responses to C5/gp41732-744 among patients who participated in a large Phase II clinical study has revealed that participants with baseline anti-C5/gp41732-744 antibody levels above 4μg/ml who received Vacc-4x had a statistically significant reduction in median viral load setpoint of log 0.94 (88%) compared to their median pre-ART viral load setpoint (p=0.005, n=12). Participants with anti-C5/gp41732-744 antibody levels below 4μg/ml who received Vacc-4x had a median viral load reduction of log 0.20 or 37% (p=0.019, n=27) compared to their median pre-ART viral load setpoint. The earlier Phase II study on which this subset analysis was based found a statistically significant 60% reduction in median viral load setpoint compared to historic viral load levels among participants who received Vacc-4x, interrupted ART for six months, and had pre-ART viral load data available. In contrast, those who received placebo did not experience a statistically significant change in viral load compared to pre-ART viral load setpoint.

Therapeutic HIV vaccines are designed to train the immune system to seek out and kill virus-producing cells in order to control the patient's HIV for prolonged periods of time. A successful therapeutic vaccine may negate the need for daily antiretroviral therapy (ART) for some people with HIV or provide an option for those who do not respond to ART.

Professor Angus Dalgleish, of St George's, University of London, said: "In spite of very effective drugs against HIV these need to be taken daily and have significant side-effects.

"The ability to replace this daily medication with a vaccine that allows several months of being off medication, not to mention the enormous financial gains that would be delivered to health services, is a step closer with these preliminary results."

Further study will be needed to confirm anti-C5/gp41732-744 antibody levels as a biomarker for improved response to Vacc-4x. Approximately 21% of participants in the Phase II study had antibody levels above 4g/ml prior to Vacc-4x vaccination.

Vacc-4x is also being studied in a clinical trial to assess whether a 'kick-kill' strategy, which is designed to reverse HIV latency using HDAC inhibitor romidepsin and to train the immune system to kill virus-producing cells using Vacc-4x, may be effective in reducing the HIV reservoir.

Source: Eurekalert


Recommended Reading

Latest Research News

Frozen Frontier: Humans Leave a Unique Microbial Mark on Mount Everest
Located at the South Col, the rocky area between Mount Everest and Lhotse serves as the final campsite for climbers as well as a frozen legacy of hardy microbes.
How Does Protein Synthesis in Diarrhea Causing Parasite Work?
The new finding is found to be valuable for screening specific medications and treatment against Giardia and other protozoan parasites.
Unlocking the Potential of CRISPR for Reversing Vision Loss
New CRISPR genome-editing strategy was found to have a positive impact in the treatment of inherited retinal diseases such as retinitis pigmentosa.
 New RT-qPCR Kit Detects Influenza, COVID-19
H3N2 Influenza: The newly developed RT-qPCR Kit to identify influenza, COVID-19 and respiratory virus has got approval from ICMR.
 Rheumatoid Arthritis: Does Taking Sex Hormones Help Women?
Does hormone replacement therapy help rheumatoid arthritis? Yes, the use of exogenous sex hormones is associated with remission in perimenopausal female patients.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Discovery of a New Biomarker may Lead to New HIV Treatment Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests